Factors affecting transmission of SARS-CoV-2 in Households of SARS-CoV-2 patients in Sub-Saharan Africa Ancillary study of the ANTICOV Study: An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19

Factors affecting transmission of SARS-CoV-2 in Households of SARS-CoV-2 patients in Sub-Saharan Africa. COVID-19

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202010718451278

Enrollment

1500

Registered

2020-10-19

Start date

2020-11-02

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Paracetamol

Hydroxychloroquine

Lopinavir Ritonavir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: For Index Cases (treated patients from the ANTICOV Study) 1. Comes from household in accessible area 2. At least 1 Household Contact (HHC) currently residing at household with index 3. Contact details of HHC provided by index case 4. Majority (over 50%) of HHC provide consent and enrol in the ANTICOV-EPI study 5. Randomised to ANTICOV For Household contacts (not treated patients living with the Index patient) 6. Member of same household as index case (household defined as sharing same cooking area) during the conduct of the study 7. Resides in household with index case before index case illness onset. 8. Majority (over 50%) of HHC provide consent and enrol in the ANTICOV-EPI study

Exclusion criteria

Exclusion criteria: Exclusion criteria of household contacts 1. Inability to provide consent 2. Majority of all contacts of index in household do not enroll

Design outcomes

Primary

Measure	Time frame
1)Seroconversion for SARS-CoV-2 IgM, IgA and IgG among household contacts and index case;2)RT-PCR SARS-CoV-2 positive results at Day 1 (index case)/D2(household contacts), 7, 14, 21, and Month 1 in household contacts and index case.;3)Secondary attack rate of infection and illness for household contacts from index cases	—

Secondary

Measure	Time frame
1) Mild, moderate and severe COVID-19 disease individual outcomes in household contacts;2) Sequence of SARS-CoV-2 in RT-PCR positive samples;3) Quantitative measure of viral load as measured by Ct values in RT-PCR;4) Quantitative levels of antibodies (IgM, IgG, IgA) against SARS-CoV-2.;5) Quantitative levels of antibodies (IgM, IgG, IgA) against other coronaviruses circulating in participating countries	—

Measure

Time frame

1) Mild, moderate and severe COVID-19 disease individual outcomes in household contacts;2) Sequence of SARS-CoV-2 in RT-PCR positive samples;3) Quantitative measure of viral load as measured by Ct values in RT-PCR;4) Quantitative levels of antibodies (IgM, IgG, IgA) against SARS-CoV-2.;5) Quantitative levels of antibodies (IgM, IgG, IgA) against other coronaviruses circulating in participating countries

—

Countries

Equatorial Guinea, Ghana, Kenya, Mozambique

Contacts

Public ContactJames Arkinstall

Head of Communication and Advocacy

media@dndi.org0041229069230

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026